Table 3.
Race-stratified distribution of GPS and Adverse Pathology at Prostatectomy by NCCN Risk Group.
| GPS Distribution Median [IQR] |
Adverse Pathology n (%) |
|||||||
|---|---|---|---|---|---|---|---|---|
| NCCN Risk Group |
All N=178 |
AA N=102 |
EA N=76 |
p- value1 |
All N=178 |
AA N=102 |
EA N=76 |
p- value2 |
| Very Low/Low N=69 |
27.0 [20.0,33.5] |
27.0 [20.0,34.0] |
27.0 [19.8,32.3] |
0.51 | 8/69 (11.6%) |
4/31 (12.9%) |
4/38 (10.5%) |
1.00 |
| Favorable Intermediate N=67 |
31.0 [26.0,40.0] |
30.0 [24.0,40.0] |
31.0 [27.0,39.5] |
0.47 | 19/67 (28.4%) |
5/35 (14.3%) |
14/32 (43.8%) |
0.01 |
| Unfavorable Intermediate N=36 |
35.0 [25.5,43.3] |
35.00 [26.5,41.8] |
35.0 [17.3,54.0] |
0.89 | 19/36 (52.8%) |
15/30 (50.0%) |
4/6 (66.7%) |
0.66 |
| High N=6 |
40.0 [36.8,46.5] |
40.0 [36.8,46.5] |
- | - | 5/6 (83.3%) |
5/6 (83.3%) |
0 (0%) |
- |
1
Using Mann-Whitney tests
2
Using Fisher’s exact test.
Abbreviations: AA: African American; EA: European American; GPS: Genomic Prostate Score; NCCN: National Comprehensive Cancer Network; AA: African American; EA: European American.